- Featured Product
- KD/KO Validated
SLC1A5/ASCT2 Polyclonal antibody
SLC1A5/ASCT2 Polyclonal Antibody for WB, IHC, IF/ICC, IF-P, FC (Intra), ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse and More (2)
Applications
WB, IHC, IF/ICC, IF-P, FC (Intra), ELISA
Conjugate
Unconjugated
Cat no : 20350-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | HeLa cells |
| Positive IHC detected in | human colon cancer tissue, human stomach cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | mouse small intestine tissue |
| Positive IF/ICC detected in | HEK-293 cells |
| Positive FC (Intra) detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:16000 |
| Immunohistochemistry (IHC) | IHC : 1:400-1:1600 |
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 2 publications below |
| WB | See 21 publications below |
| IHC | See 6 publications below |
| IF | See 4 publications below |
Product Information
20350-1-AP targets SLC1A5/ASCT2 in WB, IHC, IF/ICC, IF-P, FC (Intra), ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, pig, canine |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | SLC1A5/ASCT2 fusion protein Ag14182 |
| Full Name | solute carrier family 1 (neutral amino acid transporter), member 5 |
| Calculated Molecular Weight | 541 aa, 57 kDa |
| Observed Molecular Weight | 55-70 kDa |
| GenBank Accession Number | BC000062 |
| Gene Symbol | SLC1A5/ASCT2 |
| Gene ID (NCBI) | 6510 |
| RRID | AB_2878679 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
SLC1A5 (Solute Carrier Family 1, member 5), also named as ASCT2, a major glutamine transporter belonging to the SLC1 family and localized in the plasma membrane of several body districts. Consistent with the functions exerted by glutamine, SLC1A5 is involved in uptake of essential amino acids, activation of mTORC1 and glutamine-dependent tumor cell survival and growth. SLC1A5 is highly expressed in various malignancies and plays a critical role in the transformation, growth and survival of cancer cells (PMID: 30234109). High SLC1A5 expression is associated with poor prognosis in clear-cell renal cell carcinoma (PMID: 26599282).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| IHC protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| IF protocol for SLC1A5/ASCT2 antibody 20350-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
ACS Nano Biomimetic Nanomedicine Targeting Orchestrated Metabolism Coupled with Regulatory Factors to Disrupt the Metabolic Plasticity of Breast Cancer | ||
Theranostics PPAR-γ integrates obesity and adipocyte clock through epigenetic regulation of Bmal1. | ||
J Transl Med Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma | ||
Cell Biol Toxicol Degradation of HIF-1α induced by curcumol blocks glutaminolysis and inhibits epithelial-mesenchymal transition and invasion in colorectal cancer cells. | ||
Aging (Albany NY) The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma. | ||
Mol Ther Oncolytics Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment.
|
